[
    [
        {
            "time": "2018-07-24",
            "original_text": "Citron's Left reiterates belief AbbVie shares will fall sharply",
            "features": {
                "keywords": [
                    "Citron",
                    "reiterates",
                    "belief",
                    "AbbVie",
                    "fall",
                    "sharply"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "Citron's Left reiterates belief AbbVie shares will fall sharply",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-07-24",
            "original_text": "AbbVie prices new endometriosis drug at $10,000 a year",
            "features": {
                "keywords": [
                    "AbbVie",
                    "prices",
                    "endometriosis",
                    "drug",
                    "$10,000",
                    "year"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "AbbVie prices new endometriosis drug at $10,000 a year",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-24",
            "original_text": "Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?",
            "features": {
                "keywords": [
                    "Beat",
                    "Cards",
                    "AbbVie",
                    "Q2",
                    "Earnings"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-07-24",
            "original_text": "Merck (MRK) Q2 Earnings Coming Up: What's in the Cards?",
            "features": {
                "keywords": [
                    "Merck",
                    "Q2",
                    "Earnings",
                    "Coming",
                    "Cards"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Merck (MRK) Q2 Earnings Coming Up: What's in the Cards?",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-07-24",
            "original_text": "AbbVie Wins U.S. Approval for Endometriosis Pain Treatment",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Wins",
                    "U.S.",
                    "Approval",
                    "Endometriosis",
                    "Pain",
                    "Treatment"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "AbbVie Wins U.S. Approval for Endometriosis Pain Treatment",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-07-24",
            "original_text": "AbbVie Gets FDA Approval for Potential Blockbuster Endometriosis Treatment",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Gets",
                    "FDA",
                    "Approval",
                    "Blockbuster",
                    "Endometriosis",
                    "Treatment"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "AbbVie Gets FDA Approval for Potential Blockbuster Endometriosis Treatment",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 10,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2018-07-24",
            "original_text": "What's in Store for Cardinal Health (CAH) in Q4 Earnings?",
            "features": {
                "keywords": [
                    "Cardinal",
                    "Health",
                    "Q4",
                    "Earnings"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What's in Store for Cardinal Health (CAH) in Q4 Earnings?",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-07-24",
            "original_text": "Eli Lilly Surpasses Estimates, Reports Growth in Q2 2018",
            "features": {
                "keywords": [
                    "Eli",
                    "Lilly",
                    "Surpasses",
                    "Estimates",
                    "Growth",
                    "Q2",
                    "2018"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "Eli Lilly Surpasses Estimates, Reports Growth in Q2 2018",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-07-24",
            "original_text": "J&J’s Oncology Franchise Saw 42.2% Growth in Q2 2018",
            "features": {
                "keywords": [
                    "J&J",
                    "Oncology",
                    "Franchise",
                    "Growth",
                    "Q2",
                    "2018"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "J&J’s Oncology Franchise Saw 42.2% Growth in Q2 2018",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-07-24",
            "original_text": "Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?",
            "features": {
                "keywords": [
                    "Strong",
                    "HIV",
                    "Sales",
                    "Fuel",
                    "Gilead",
                    "Q2",
                    "Earnings"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]